(Q34655436)

3 August 2017

title

Chondroitin and glucosamine in the management of osteoarthritis: an update (English)

1 reference

3 August 2017

0 references

0 references

1

Yves Henrotin

1 reference

3 August 2017

Cécile Lambert

2

1 reference

3 August 2017

publication date

1 October 2013

1 reference

Current Rheumatology Reports

3 August 2017

published in

1 reference

3 August 2017

volume

15

1 reference

3 August 2017

issue

10

1 reference

3 August 2017

page(s)

361

1 reference

https://scigraph.springernature.com/pub.10.1007/s11926-013-0361-z

3 August 2017

exact match

0 references

cites work

Oral glucosamine increases expression of transforming growth factor β1 (TGFβ1) and connective tissue growth factor (CTGF) mRNA in rat cartilage and kidney: implications for human efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Effects of chondroitin sulfate and interleukin-1 beta on human articular chondrocytes cultivated in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

The effects of oral glucosamine on joint health: is a change in research approach needed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Pharmacoproteomic study of three different chondroitin sulfate compounds on intracellular and extracellular human chondrocyte proteomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Secretome analysis of chondroitin sulfate-treated chondrocytes reveals anti-angiogenic, anti-inflammatory and anti-catabolic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Antioxidant activity of chondroitin sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Chondroitin sulphate: antioxidant properties and beneficial effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Chondroitin-4-sulphate inhibits NF-kB translocation and caspase activation in collagen-induced arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Glycosaminoglycans reduced inflammatory response by modulating toll-like receptor-4 in LPS-stimulated chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Experimental pharmacology of glucosamine sulfate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Effects of low molecular weight chondroitin sulfate on type II collagen-induced arthritis in DBA/1J mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Chondroitin sulfate increases hyaluronan production by human synoviocytes through differential regulation of hyaluronan synthases: Role of p38 and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Immunomodulatory and anti-inflammatory effects of chondroitin sulphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Therapeutic efficacy of undenatured type-II collagen (UC-II) in comparison to glucosamine and chondroitin in arthritic horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Interpretation of metaanalyses: pitfalls should be more widely recognized

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Differential down-regulation of COX-2 and MMP-13 in human skin fibroblasts by glucosamine-hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes--implications for osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Glucosamine sulfate reduces prostaglandin E(2) production in osteoarthritic chondrocytes through inhibition of microsomal PGE synthase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Chondroitin sulphate: an effective joint lubricant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Chondroprotective effects of glucosamine involving the p38 MAPK and Akt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Osteoarthritis: a disease of the joint as an organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Suppression of cytokine production in lipopolysaccharide-stimulated mouse macrophages by novel cationic glucosamine derivative involves down-regulation of NF-kappaB and MAPK expressions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Evaluation of the effect of glucosamine on an experimental rat osteoarthritis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Effects of sodium-hyaluronate and glucosamine-chondroitin sulfate on remodeling stage of tenotomized superficial digital flexor tendon in rabbits: a clinical, histopathological, ultrastructural, and biomechanical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E₂ and matrix metalloproteinases synthesis in interleukin-1β-stimulated osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Long-term oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up-regulation of MMP-3 mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Variable effects of 3 different chondroitin sulfate compounds on human osteoarthritic cartilage/chondrocytes: relevance of purity and production process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Modulation of inflammation by chondroitin sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Glucosamine for pain in osteoarthritis: why do trial results differ?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Analytical aspects of pharmaceutical grade chondroitin sulfates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Quality of different chondroitin sulfate preparations in relation to their therapeutic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Glucosamine sulfate reduces experimental osteoarthritis and nociception in rats: association with changes of mitogen-activated protein kinase in chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Osteoarthritis - an untreatable disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0361-Z

Osteoarthritis: a tale of three tissues.

21 January 2018

1 reference

12 December 2020

Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes

1 reference

12 December 2020

Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes

1 reference

12 December 2020

Chondroitin sulfate modulation of matrix and inflammatory gene expression in IL-1beta-stimulated chondrocytes--study in hypoxic alginate bead cultures

1 reference

12 December 2020

Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis.

1 reference

12 December 2020

Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center

1 reference

12 December 2020

The glucosamine controversy; a pharmacokinetic issue.

1 reference

12 December 2020

Urinary glycosaminoglycans in horse osteoarthritis. Effects of chondroitin sulfate and glucosamine

1 reference

12 December 2020

Influence of polysulphated polysaccharides and hydrocortisone on the extracellular matrix metabolism of human articular chondrocytes in vitro.

1 reference

12 December 2020

The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis

1 reference

12 December 2020

Effect of glucosamine, a therapeutic agent for osteoarthritis, on osteoblastic cell differentiation

1 reference

12 December 2020

Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis

1 reference

12 December 2020

Chondroitin sulfate and hyaluronic acid (500-730 kda) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes.

1 reference

12 December 2020

Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis.

1 reference

12 December 2020

Natural chondroitin sulphates increase aggregation of proteoglycan complexes and decrease ADAMTS-5 expression in interleukin 1 beta-treated chondrocytes

1 reference

12 December 2020

Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial

1 reference

12 December 2020

Glucosamine therapy for treating osteoarthritis

1 reference

12 December 2020

The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate

1 reference

12 December 2020

Chondroitin sulfate effect on induced arthritis in rats

1 reference

12 December 2020

Assorted effects of TGFbeta and chondroitinsulfate on p38 and ERK1/2 activation levels in human articular chondrocytes stimulated with LPS

1 reference

12 December 2020

Anti-arthritic action mechanisms of natural chondroitin sulfate in human articular chondrocytes and synovial fibroblasts

1 reference

12 December 2020

Effects of glucosamine derivatives and uronic acids on the production of glycosaminoglycans by human synovial cells and chondrocytes

1 reference

12 December 2020

10.1007/S11926-013-0361-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1009417498

0 references

Fatcat ID

release_upp2wxlfwrfajnt2pgmf2tifj4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/upp2wxlfwrfajnt2pgmf2tifj4

24 November 2022

mapped directly with Wikidata item

1 reference